Serina Therapeutics, Inc. (SER) Form 8-K — Jul 23, 2026
Serina Therapeutics entered into an Amended and Restated Employment Agreement with CEO Steve Ledger, effective July 19, 2026. The agreement updates the terms of his employment, which were previously governed by a September 2024 agreement. The new terms establish an annual base salary of $500,000 and a target annual bonus of 50% of that base salary. The agreement also confirms previously granted stock options and maintains eligibility for future equity awards at the board's discretion.
Key figures
- Base Salary
- 500000
- Non Compete Years
- 2
- Target Bonus Percent
- 50%
- Severance Multiple CIC
- 1.5
- Severance Months Standard
- 12
Price after filing
Close on the filing date to close N calendar days later (from $2.09). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.